10x Genomics (TXG) CEO sells 9,632 shares to cover RSU tax

Rhea-AI Filing Summary

10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported an open-market sale of 9,632 shares of Class A common stock on February 23, 2026 at an average price of $18.5764 per share. The shares were sold to cover tax withholding obligations related to vesting restricted stock units.

After this transaction, Saxonov directly held 1,061,924 Class A shares. In addition, indirect holdings as trustee included 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust.

Insider Trade Summary

Net Seller: 9,632 shares ($178,928)

Net Sell 4 txns

Insider Saxonov Serge

Role Chief Executive Officer

Sold 9,632 shs ($179K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	9,632	$18.5764	$179K
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 1,061,924 shares (Direct); Class A Common Stock — 27 shares (Indirect, See footnote)

Footnotes (1)

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/23/2026		S(1)		9,632	D	$18.5764	1,061,924	D
Class A Common Stock								27	I	See footnote(2)
Class A Common Stock								213,250	I	See footnote(3)
Class A Common Stock								58,000	I	See footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

2. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

3. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

4. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TXG CEO Serge Saxonov report on this Form 4?

Serge Saxonov reported selling 9,632 shares of 10x Genomics Class A common stock. The sale occurred on February 23, 2026 at an average price of $18.5764 per share and was conducted to cover tax withholding obligations from vesting restricted stock units.

Was the TXG CEO’s share sale a discretionary sale or for tax withholding?

The reported sale was made to cover tax withholding obligations tied to vesting restricted stock units. This means the transaction was primarily to satisfy tax requirements rather than a discretionary portfolio sale, according to the footnote disclosure in the Form 4.

How many TXG shares does CEO Serge Saxonov hold directly after this transaction?

After the reported sale, Serge Saxonov directly held 1,061,924 shares of 10x Genomics Class A common stock. This figure reflects his direct ownership position following the 9,632-share disposition executed on February 23, 2026 to cover tax withholding obligations.

What indirect TXG share holdings are associated with trusts for which the CEO is trustee?

Indirect holdings include 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust. Serge Saxonov serves as trustee for these trusts, and the Form 4 lists these positions as indirect ownership.

How many total TXG shares were sold in this Form 4 transaction and at what price?

The Form 4 reports a sale of 9,632 shares of 10x Genomics Class A common stock. The average sale price was $18.5764 per share, with the transaction dated February 23, 2026 and identified as an open-market sale to cover tax withholding.

Does the TXG Form 4 show any insider share purchases by the CEO?

The Form 4 does not report any purchases by CEO Serge Saxonov. It shows one open-market sale of 9,632 shares to cover tax withholding and several indirect holdings associated with trusts, without any buy transactions disclosed in this specific filing.